- Home
- WSC vs ERAS Comparison
WSC vs ERAS Comparison
Compare WSC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WSC | ERAS |
|---|---|---|
| Founded | 1944 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.5B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WSC | ERAS |
|---|---|---|
| Price | $25.71 | $13.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $24.14 | $14.25 |
| AVG Volume (30 Days) | 2.7M | ★ 4.4M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $2,281,446,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.31 | N/A |
| P/E Ratio | $170.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.91 | $1.24 |
| 52 Week High | $31.88 | $24.28 |
Technical Indicators
Market Signals| Indicator | WSC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 58.46 | 53.80 |
| Support Level | $20.99 | $12.91 |
| Resistance Level | $28.76 | $16.14 |
| Average True Range (ATR) | 1.01 | 0.90 |
| MACD | -0.11 | 0.51 |
| Stochastic Oscillator | 73.97 | 64.53 |
Price Performance
Historical ComparisonAbout WSC WillScot Mobile Mini Holdings Corp.
WillScot Holdings Corp designs, delivers, and services on-site, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company include modular office complexes, mobile offices, classrooms, blast-resistant modules, clearspan structures, sanitation solutions, portable storage containers, and climate-controlled containers and trailers.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.